openPR Logo
Press release

Early Dementia detection via App receives medical device status

01-08-2019 07:03 PM CET | Health & Medicine

Press release from: DST

The DST is available on Apple, Google, Amazon appstores.

The DST is available on Apple, Google, Amazon appstores.

- The DST (Dementia Screening Test) App has been recognized by Health Authorities as a Medical Device.
- Early Dementia stages are reliably detected, before the brain damages become irreversible.
- Sensitivity above 96%, significantly higher than with the established tests (e.g., MMSE 71%).

Dementia is a rapidly increasing social problem of a rapidly aging society. Because until today, there is no effective therapy for advanced stages of dementia. Therefore, effective screening concepts are needed, to detect early stages reliably across the population, and to start treatment before the brain damages become irreversible.

Demand for Dementia Screening Tests has increased significantly in recent years, as the focus of dementia research has changed from diagnosis and treatment at the clinically symptomatic stage, to pre-symptomatic neuroprotective therapies. Dementia should no longer be regarded as a disease of the elderly, but as one of middle-aged people which is clinically quiet for a long time. 1)

To detect the disease at this early stage, special sensitive tests are necessary, which are also widely used without any suspicion, to have an impact at population level as well as at an individual level. The classical questionnaire-based self-assessments are not very suitable, because they identify the disease only with existing symptoms and thus generally too late.

A group of physicians has therefore developed a simple, validated, and easily accessible Dementia test - the DST (Dementia Screening Test - www.demenz-test.com). The reliability of the test results especially in the asymptomatic pre-dementia stage has been proven by clinical studies. The test has therefore been recognized as a medical device by the competent authorities, including the EU, Switzerland, Iceland, Norway, Liechtenstein, Canada and Australia.

1) The Lancet Commission for Dementia prevention, intervention, and care (2017) 390: 2673–734: Dementia prevention, intervention, and care

Changing Dementia - that is the vision of the DST.
The DST was developed by a group of physicians to reliably detect early stages of Dementia, as a basis for treatment before obvious symptoms develop.

Dr. med. Sebastian Horn
Friedrichstr. 67
10117 Berlin, Germany

www.demenz-test.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Early Dementia detection via App receives medical device status here

News-ID: 1480417 • Views: 561

More Releases from DST

07-10-2019 | Health & Medicine
DST
Dementia begins in the mid-40s - early detection crucial
We know today that those who will probably be demented in 15 to 20 years are already experiencing their first brain changes today. In other words, in many people it is already clear at the age of 40 to 50 whether they start to develop dementia. Fortunately, our brain can compensate individual deficits so well for 15 to 20 years that the affected person and the environment do not notice
02-11-2019 | Health & Medicine
DST
Dementia test predicts disease 18 years before symptoms
• Multi-dimensional cognitive tests detect restrictions at least 18 years prior to clinical Dementia symptoms. • Good therapy options exist for this pre-symptomatic phase. It has been known for several years that cognitive tests can "predict" dementia 10-12 years prior to clinical symptoms - or more precisely: they can recognize initial limitations in people who are not clinically conspicuous / symptomatic in everyday life, but who are later diagnosed with dementia. The
12-11-2018 | Health & Medicine
DST
New App detects dementia risks early
• The App is certified as a Medical Device. • Early stages are reliably detected, before the brain damage becomes irreversible. • Sensitivity above 96%, significantly higher than with the established tests (e.g., MMSE 71%). • Now available for free during pre-launch. Dementia is a rapidly increasing social problem of a rapidly aging society. Because until today there is no effective therapy for advanced stages of dementia. Therefore, effective screening tests are needed to detect early stages

All 4 Releases


More Releases for Dementia

12-11-2018 | Health & Medicine
DST
New App detects dementia risks early
• The App is certified as a Medical Device. • Early stages are reliably detected, before the brain damage becomes irreversible. • Sensitivity above 96%, significantly higher than with the established tests (e.g., MMSE 71%). • Now available for free during pre-launch. Dementia is a rapidly increasing social problem of a rapidly aging society. Because until today there is no effective therapy for advanced stages of dementia. Therefore, effective screening tests are needed to detect early stages
2nd International Conference on Dementia and Dementia Care
Breakthrough in Dementia Research and Care Event Name: 2nd International Conference on Dementia and Dementia Care (Dementia 2019) Theme: Breakthrough in Dementia Research and Care Aim and Scope: Dementia is an umbrella term used to describe a set of symptoms that occur when the brain is affected by disease. There’s currently no cure and no treatment that slows or stops its progression, but there are things you can do to help reduce the
11th International Conference on Vascular Dementia
Can We Cure Dementia, Vascular Dementia and Alzheimer's disease? It’s our pleasure to invite all the participants from all over the world to attend the 11th International Conference on Vascular Dementia which is held during February 15-16, 2019 Amsterdam| Netherlands. Vascular Dementia conference will assemble illustrious speakers, Researchers, Nobel laureates, Neurologists, and Neuroscience researchers from both academic and health care professionals will join this event to discuss their views and research. The
2nd International conference on Dementia and Dementia Care
Breakthrough in Dementia Research and Care Event Name: 2nd International Conference on Dementia and Dementia Care (Dementia 2019) Theme: Breakthrough in Dementia Research and Care Aim and Scope: Dementia is an umbrella term used to describe a set of symptoms that occur when the brain is affected by disease. There’s currently no cure and no treatment that slows or stops its progression, but there are things you can do to help reduce the
Global Alzheimer’s disease, Dementia and Ageing Awareness
Lexis brings in a new spin on conferences by presenting the latest scientific improvements in the fields of Neurology and Neuroscience. Zurich is all set for an amazing event as LEXIS proudly presents the “Global Alzheimers, Dementia and Ageing Awareness” slated on July 17-18, 2019 at Zurich, Switzerland. The theme of the conference is “Global Voice and Awareness on Alzheimers Disease and Dementia Care”. Avenue Roger VAndendriessche, 18 at 1150 BRUSSELS Avenue
Dementia - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Dementia - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia - Pipeline Review, H2 2017, provides an overview of the Dementia (Central Nervous System) pipeline landscape. Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with